CN102406893A - 一种治疗银屑病的中成药 - Google Patents
一种治疗银屑病的中成药 Download PDFInfo
- Publication number
- CN102406893A CN102406893A CN2011103762963A CN201110376296A CN102406893A CN 102406893 A CN102406893 A CN 102406893A CN 2011103762963 A CN2011103762963 A CN 2011103762963A CN 201110376296 A CN201110376296 A CN 201110376296A CN 102406893 A CN102406893 A CN 102406893A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese patent
- patent medicine
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 93
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 28
- 241000628997 Flos Species 0.000 claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 14
- 239000010231 banlangen Substances 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 230000001185 psoriatic effect Effects 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 14
- 238000005516 engineering process Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 claims description 7
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 7
- 241000245240 Lonicera Species 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- -1 sublimed preparation Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 33
- 201000010099 disease Diseases 0.000 abstract description 16
- 231100000957 no side effect Toxicity 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000004630 mental health Effects 0.000 abstract description 2
- 239000008280 blood Substances 0.000 description 36
- 210000004369 blood Anatomy 0.000 description 34
- 206010040882 skin lesion Diseases 0.000 description 26
- 231100000444 skin lesion Toxicity 0.000 description 26
- 208000002193 Pain Diseases 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 10
- 206010000496 acne Diseases 0.000 description 8
- 201000000736 Amenorrhea Diseases 0.000 description 7
- 206010001928 Amenorrhoea Diseases 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 7
- 231100000540 amenorrhea Toxicity 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 206010037844 rash Diseases 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 208000004998 Abdominal Pain Diseases 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 5
- 206010037888 Rash pustular Diseases 0.000 description 5
- 206010040943 Skin Ulcer Diseases 0.000 description 5
- 208000001780 epistaxis Diseases 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000012567 medical material Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 208000029561 pustule Diseases 0.000 description 5
- 231100000019 skin ulcer Toxicity 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000001840 Dandruff Diseases 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- 208000015220 Febrile disease Diseases 0.000 description 4
- 206010027514 Metrorrhagia Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 206010040844 Skin exfoliation Diseases 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 230000008092 positive effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000008736 traumatic injury Effects 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000035618 desquamation Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000002175 menstrual effect Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 206010034754 petechiae Diseases 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- 206010052369 Encephalitis lethargica Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020741 Hyperpyrexia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003119 painkilling effect Effects 0.000 description 2
- 230000001314 paroxysmal effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 201000002498 viral encephalitis Diseases 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- KDPFMRXIVDLQKX-ISGXEFFDSA-N (+)-Curdione Natural products CC(C)[C@@H]1CC(=O)[C@@H](C)CC\C=C(C)/CC1=O KDPFMRXIVDLQKX-ISGXEFFDSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000002045 Ancylostomiasis Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000033211 Ankylostomiasis Diseases 0.000 description 1
- 241000233788 Arecaceae Species 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241001131815 Egretta garzetta Species 0.000 description 1
- 206010015278 Erythrodermic psoriasis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- KDPFMRXIVDLQKX-NHFJXKHHSA-N Germacr-1(10)-ene-5,8-dione Chemical compound CC(C)[C@@H]1CC(=O)[C@@H](C)CC\C=C(C)\CC1=O KDPFMRXIVDLQKX-NHFJXKHHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020376 Hookworm infection Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- ISFMXVMWEWLJGJ-NZBPQXDJSA-N curcumenol Chemical compound CC1=C[C@](O2)(O)C(=C(C)C)C[C@@]22[C@@H](C)CC[C@H]21 ISFMXVMWEWLJGJ-NZBPQXDJSA-N 0.000 description 1
- KDPFMRXIVDLQKX-UHFFFAOYSA-N curdione Natural products CC(C)C1CC(=O)C(C)CCC=C(C)CC1=O KDPFMRXIVDLQKX-UHFFFAOYSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000002832 shoulder Anatomy 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000037377 skin turgor Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及银屑病的治疗技术领域,尤其涉及一种治疗银屑病的中成药的技术领域。本发明是采用如下技术方案的:一种治疗银屑病的中成药,其特殊之处是由下列重量份的药物制备而成:丹皮、丹参、生地、茯苓、茺蔚子、炒荆芥、板蓝根、金银花、紫草、白癣皮、莪术、红花、乌梅、煅牡蛎、赤芍、甘草。本发明所与现有技术相比具有提供了一种能消除患者的疾患,促进身心健康,同时具有治疗费用低、患者服药方便、疗效快、无副作用的治疗银屑病的突出的实质性特点和显著的进步。
Description
技术领域
本发明涉及银屑病的治疗技术领域,尤其涉及一种治疗银屑病的中成药的技术领域。
背景技术
银屑病是一种常见的慢性皮肤病,其主要是在红斑上反复出现多层银白色干燥鳞屑。中医古称之为“白疕”,古医籍亦有称之为松皮癣。西医称为银屑病(Psoriasis),俗称牛皮癣,其出现大小不等的丘疹,红斑,表面覆盖着银白色鳞屑,边界清楚,男性多于女性。银屑病容易复发,春冬季节容易复发或加重,而夏秋季多缓解。发病的部位以头皮最常见,其次为小腿、肘部、背部、上臂、前臂、膝盖、胸部以及腹部和臀部等。常呈对称性分布,亦可沿皮神经分布呈线状排列。
患者由于搔抓,患部及其周围可伴有抓痕、出血点或血痂,其附近也可有新的扁平小丘疹出现;自觉阵发性奇痒,被衣摩擦与汗渍时更剧,入夜尤甚,搔之不知痛楚。情绪波动时,瘙痒也随之加剧。因瘙痒可影响工作和休息,患者常伴有失眠、头昏、烦躁症状,因该病病程缓慢,常数年不愈,反复发作,往往给患者带来极大的身心痛苦和经济负担。因该病顽固难治,仍被列为当今世界皮肤科领域的重要研究课题,是全世界皮肤科重点防治疾病之一。在银屑病防治上,中医、西医及中西医结合都有许多成药和成功的治疗方法,但有的也给患者带来了不少的麻烦,如西医抗癌药和激素类药物的使有,其严重的副作用给患者的身体带来了较严重的摧残,其疗效差、反复发作令患者不满意,不仅给患者带来了许多的痛苦,而且带来了高额的医疗费用。因此,寻求一种新的、能消除患者的疾患、具有服药方便、疗效快、无副作用的治疗银屑病的中成药仍是本技术领域的技术人员亟待解决的课题。
发明内容:
本发明所要解决的技术问题是克服现有技术的不足,而提供一种以消除患者的疾患,促进身心健康,同时具有治疗费用低、患者服药方便、疗效快、无副作用的治疗银屑病的中成药。
为解决上述技术问题,本发明是采用如下技术方案的:一种治疗银屑病的中成药,其特殊之处是由下列重量份的药物制备而成:丹皮15-45份、丹参20-50份、生地15-45份、茯苓15-45份、茺蔚子15-45份、炒荆芥10-40份、板蓝根15-45份、金银花15-45份、紫草15-45份、白藓皮15-45份、莪术15-45份、红花10-30份、乌梅30-70份、煅牡蛎60-90份、赤芍15-45份、甘草5-35份。
为进一步解决上述技术问题,上述药物重量份的优选方案是:丹皮25-35份、丹参30-40份、生地25-35份、茯苓25-35份、茺蔚子25-35份、炒荆芥20-30份、板蓝根25-35份、金银花25-35份、紫草25-35份、白藓皮25-35份、莪术25-35份、红花15-25份、乌梅40-60份、煅牡蛎70-80份、赤芍25-35份、甘草10-30份。
为进一步解决上述技术问题,上述药物重量份的最佳方案是:丹皮30份、丹参35份、生地30份、茯苓30份、茺蔚子30份、炒荆芥25份、板蓝根30份、金银花30份、紫草30份、白藓皮30份、莪术30份、红花20份、乌梅50份、煅牡蛎75份、赤芍30份、甘草20份。
上述所述的中成药按照中药常规制备技术制成丸剂、丹剂、散剂、片剂、膏剂、汤剂及胶囊装粉剂不同的内服药剂型。
上述所述的中成药还含有药物赋形剂。
上述所述的中成药作为治疗银屑病疾病的应用。
本发明所述的中成药的组方原则是:以调节血流循环,清心火、祛风利湿、益肾解毒、镇疼止痒、凉血化斑、增进毛细血管扩张,提高人体免疫功能,从而达到治疗银屑病的目的。本发明具有药物配伍得当、组方合理,其所述各味药物的功效为:
丹皮:味苦,性凉、微寒。归心,肝,肾,肺经。功效主治:清热凉血;活血散瘀。温热病热入血分;发斑;吐衄;热病后期热伏阴分发热;阴虚骨蒸潮热;血滞经闭;痛经;痈肿疮毒;跌扑伤痛;风湿热痹。
丹参:味苦、微辛,性微寒;入心、脾、肝、肾径;功效:具有活血祛瘀,养血安神,凉血消肿的功效;主治:瘀血头、胸、胁、腹疼痛,积聚,月经不调,痛经经闭,产后瘀滞腹痛,关节痹痛,跌打瘀肿,温病心烦,血虚心悸,疮疡肿毒,丹疹疥癣。
生地:别名:地黄、地髓、阳精、苄根,为玄参科植物。性平、味苦,中医学上以茎藤入药,功能清热解毒、活血通经,主治关节疼痛等症。
茯苓:味甘、淡;性平;归心、脾、肺、肾经;功效:渗湿利水、健脾和胃、宁心安神;主治:小便不利、水肿胀满、痰饮咳逆、呕吐、脾虚食少、泄泻、心悸不安、失眠健忘、遗精白浊。
茺蔚子:味辛、微苦,性微寒;归心胞、肝经;功能主治:活血调经,疏风清热;治妇女月经不调,崩中带下,产后瘀血作痛;肝热头痛,目赤肿痛,或生翳膜。
炒荆芥:味辛、性微温、归肺、肝经,具有解表散风、透疹、消疮、止血的功效,常用于治疗感冒、麻疹透发不畅、便血、崩漏、鼻衄等疾病。
板蓝根:性寒、味苦,无毒。归肝、胃经;功效:清热,解毒,凉血,利咽;主治:温毒发斑;高热头痛;大头瘟疫;舌绛紫暗,烂喉丹痧;丹毒;痄腮;喉痹;疮肿、痈肿;水痘;麻疹;肝炎;流行性感冒,流脑,乙脑,肺炎,神昏吐衄,咽肿,火眼,疮疹;可防治流行性乙型脑炎、急慢性肝炎、流行性腮腺炎、骨髓炎。
金银花:别名:忍冬花、鹭鸶花、银花、二花、金藤花、双苞花、金花、二宝花;性寒、味甘;归经:肺;胃经功效:清热解毒主治:温病发热;热毒血痢;痈肿疔疮;喉痹及多种感染性疾病。
紫草:性寒、味苦,甘、平,归入心、肝经。功效:凉血,活血,清热,解毒。主治温热斑疹,湿热黄疸,紫癜,吐、衄、尿血,淋浊,热结便秘,烧伤,湿疹,丹毒,痈疡等症。
白藓皮:性寒、味苦,归脾、胃、膀胱、小肠经;功效为清热燥湿,祛风,解毒;临床用于湿热疮毒、遍身脓窠、黄水淋漓,以及皮肤瘙痒、疮癣疥癞、阴部肿痛等症、白藓皮为祛风、除湿热的药品,并可渗湿热于下窍,适用于疮癣湿痒等症,常配合苦参、地肤子等药同用,既可内服,亦可煎汤外洗。
莪术:化学成份:根茎含挥发油,油中含的成分有莪术呋喃酮、表莪术呋喃酮、莪术呋喃烃、莪术双酮、莪术醇、樟脑、龙脑等。性温、味苦、辛,入肝、脾经。功能:破血行气,消积止痛。主要用于血瘀腹痛、肝脾肿大、心腹胀痛,积聚,妇女血瘀经闭,跌打损伤作痛饮食积滞。行气止痛,破血消积:用于气滞血瘀之经闭、胸胁痛、腹痛及症瘕肿块等。常配三棱。消食化积:用于饮食积滞之胃腹胀痛,常配焦麦芽、焦槟榔。
红花:味辛、性温,归心、肝经。功能主治:活血通径、散瘀止痛。用于经闭、痛经、恶露不行、症瘕痞块、跌打损伤。适用各种静脉曲张,末梢神经炎,血液循环。活血通经,祛瘀止痛,气香行散,入血分具有活血通经,祛瘀止痛的功效,主治痛经,经闭,产后血晕,瘀滞腹痛,胸痹心痛,血积,跌打瘀肿,关节疼痛,中风瘫痪,斑疹紫暗。
乌梅:味酸,性温;归入肝、脾、肺、大肠经。功能主治:收敛生津,安蛔驱虫。治久咳,虚热烦渴,久疟,久泻,痢疾,便血,尿血,血崩,蛔厥腹痛、呕吐,钩虫病,牛皮癣,胬肉。
煅牡蛎:将洗净的牡蛎,置无烟炉火上煅至灰白色,取出放凉,碾碎。味咸、性微寒;归肝、肾经;功能与主治:平肝潜阳、重镇安神、软坚散结、收敛固涩。主治:主眩晕耳鸣、惊悸失眠、瘰疬瘿瘤、症瘕痞块、自汗盗汗、遗精、崩漏、带下。
赤芍:味酸、苦,性凉。入肝、脾经。功效:行瘀,止痛,凉血,消肿。主治:治瘀滞经闭,疝瘕积聚,腹痛,胁痛,衄血,血痢,肠风下血,目赤,痈肿。
甘草:味甘,性平;归十二经。功效:有解毒、祛痰、止痛、解痉以至抗癌等药理作用。在中医上,甘草补脾益气,滋咳润肺,缓急解毒,调和百药。临床应用分“生用”与“蜜炙”之别。生用主治咽喉肿痛,痛疽疮疡,胃肠道溃疡以及解药毒、食物中毒等;蜜炙主治脾胃功能减退,大便溏薄,乏力发热以及咳嗽、心悸等。
中医药学理论认为:初起多为风湿热之邪阻滞肌肤,或颈项多汗,硬领摩擦等所致;病久耗伤阴液,营血不足,血虚生风生燥,肌肤失养而成;血虚肝旺,情志不遂,郁闷不舒,或紧张劳累,心火上炎,以致气血运行失职,凝滞肌肤,易成诱发的重要因素,且致病情反复发作。总之,情志内伤、风邪侵袭是本病发病的诱发因素,营血失和、经脉失疏、气血凝滞则为其病机。因此,
本发明遵循中医“君臣佐使”的组方原则,全部成分来自于中国《药典》第五版收载的药物,诸药相和共具有温补肝脾,散风除湿,调和气血,通经活络、活血化瘀、扶正驱邪,调节免疫功能,改善皮肤微循环,达到治疗和预防银屑病疾病、疗效确切,无毒副作用,各种中药制剂服用方便。
本发明中成药临床使用结果表明,具有如下优点:
1、本发明选用的中药各组份符合中华人民共和国药品管理法之规定,利用各味中药的综合作用治疗和预防银屑病疾病,对人体无毒无害。经小白鼠和大白鼠的急性毒性试验和蓄积性毒性试验表明被试验的动物未见任何毒性反应,经解剖观察血象、肝功能、各脏器组织形态学所见与对照组比较无差异,证明其药物安全可靠。
2、本发明所述的中成药制剂无须煎煮、无苦涩感,药品中富含蛋白质、葡萄糖、葡萄糖醛酸、挥发油、果胶、果糖、有机酸、卵磷脂、维生素、氨基酸,还含皂甙、植物甾醇、钙等多种微量元素,有利于人体吸收,增强体质,且服用方便。
3、本发明所述的中成药制剂不仅可有效的治疗银屑病疾病,而且对银屑病疾病的预防作用也非常明显,特别是通过药物之间的相互协同,增强药物各自治疗特性,通过通经活络和调节免疫功能,提高了患者身体内在的正气和身心健康及生存质量,较好的达到治愈康复效果。
下面通过临床应用进一步说明本发明中成药对治疗银屑病的效果。
一、临床诊断标准:
发病的部位以头皮最常见,其次为小腿、肘部、背部、上臂、前臂膝盖、胸部以及腹部和臀部等。常呈对称性分布,亦可沿皮神经分布呈线状排列。皮损初起为有聚集倾向的多角形扁平丘疹,皮色正常或略潮红,表面光泽或覆有菲薄的糠皮状鳞屑,以后由于不断地搔抓或摩擦,丘疹逐渐扩大,互相融合成片,继之则局部皮肤增厚,纹理加深,互相交错,表面干燥粗糙,并有少许灰白色鳞屑,而呈苔藓样变,皮肤损害可呈圆形或不规则形斑片,边界清楚,触之粗糙。由于搔抓,患部及其周围可伴有抓痕、出血点或血痂,其附近也可有新的扁平小丘疹出现。自觉阵发性奇痒,被衣摩擦与汗渍时更剧,入夜尤甚,搔之不知痛楚。情绪波动时,瘙痒也随之加剧。因瘙痒可影响工作和休息,患者常伴有失眠、头昏、烦躁症状。本病病程缓慢,常数年不愈,反复发作。
临床上按其发病部位、皮损多少分为泛发型和局限型两种。局限型,皮损仅见于颈项等局部,为少数境界清楚的苔藓样肥厚斑片;泛发型,分布较广泛,好发于头、四肢、肩腰部等处,甚至泛发全身各处,皮损特点与局限型相同。
根据银屑病的临床表现和病理特征,一般分为以下四种类型
1、寻常型银屑病:皮疹一般发生在头皮、躯干、四肢伸侧,是在皮肤上出现红色的丘疹,并逐渐扩大融合成斑片或斑块,表面有较厚的银白色磷屑,形状不规则,有的有地图或岛屿样外观,有的皮损较小,较多,呈满天星外观,鳞屑层一层脱落,轻轻刮掉皮屑可看到薄薄的一层红膜,刮除红膜即可看到小小的出血点,有人称为血露,医学上又叫筛状出血,这就是寻常型牛皮癣临床特征。
2、红皮病型银屑病:是较严重,较少见的一种,此型是指在约全身皮肤的70%以上呈弥漫性红色,暗红色浸润性皮损,表面有大量糠皮样皮屑,有时在腋下,大腿根部和脐部因肿胀而使表皮剥脱和渗出,口咽鼻及眼结膜可充血发红,患者常有发热畏寒,头疼及全身不适等症状。
3、脓疱性银屑病:分泛发性及局限性。泛发性脓疱型牛皮癣多为急性发病,可在数日至数周内脓疱泛发全身,先有密集的针尖大小潜在的小脓疱,很快融合成脓湖,常伴有高热、关节肿痛及全身不适,血常规化验可见白细胞增多,脓疮干涸后,随即脱屑,皮屑脱落后,又有新的脓疮出现。局限性脓疱型牛皮癣以掌趾脓疱型牛皮癣多见,在双手掌和足趾部有对称性红斑,红斑上出现针头大到栗大小到小脓疱:大约1-2周后自行干涸,脱屑后又有新的脓疱出现,反复绵延,病程顽固。
4、关节病性银屑病:很少见,任何年龄均可发生,可同时发生于大小关节,但常见是手腕、手指及足趾小关节,脊柱关节也可发生。病变的关节有红肿、疼痛、严重的关节腔有积液,关节附近皮肤肿胀活动受限,久之关节僵直,严重时X线下可见关节被破坏的情况,血沉快,常伴发热等全身症状,但类风湿凝集因子为阴性,关节炎型牛皮癣、皮肤损害多伴有厚厚的像蛎壳状的皮损,也可仅有寻常型牛皮癣的红斑和银屑的皮肤损害。
鉴别诊断
1.慢性湿疮多有皮肤潮红、丘疹、水疱、糜烂、渗出等急性湿疮的发病过程,皮损以肥厚粗糙为主,伴有出疹、水疱、糜烂、渗出,边界欠清,病变多在四肢屈侧。
2.皮肤淀粉样变多发在背部和小腿伸侧,皮肤为高粱米大小的圆顶丘疹,色紫褐,质较硬,密集成群,角化粗糙。
3.白疙皮损基底呈淡红色,上覆以银白色糠秕状鳞屑,剥去后有薄膜现象和点状出血。
二.病例的选择
对于符合上述疾病的患者均可作为病例进行观察,尤其对体弱多病、中老年人、妇女、儿童更是作为首选病例进行观察;观察的方法则通过望、问、闻、切的方法对患者进行全面观察;而对于病情较重患者不分年龄、性别,一律作为观察治疗的直接受试对象。
三.用药方法
根据银屑病患者的病情轻重程度、患病时间的长短,采用内用口服本发明所述的中成药进行治疗银屑病,其服药方法为:一日三次,每次6-12克,温开水送服;饭前、饭后服用均可。初服期为30天,药量可增倍,此后按常规药量进行连续服药,三个月为一个疗程进行观察和疗效判断。本发明所述的中成药因为中药制剂、组方合理,经临床用药毒性试验证明无毒副作用,因此,患者在治疗期间可较长时间服用本发明所述的中成药,且在服药期间饮食方面无需忌口。
四.疗效判定标准
由于银屑病为易诊难治的皮肤病,因而银屑病的临床治疗观察指标及疗效判断标准分为:治疗期间、治疗结束后和远期追访三个时期。
1.治疗期临床观察及疗效判断标准
(1)临床观察
①鳞屑:表皮细胞的增殖加速和棘层增生,导致角质层的角化过度,使表皮换新率较正常表皮快7-8倍,即每3天左右脱屑一层。用药后的判断标准为:鳞屑逐渐减少或无新的皮肤损害出现为有效,反之为无效。
②基底:其表现为基底浸润、肥厚,表明皮细胞的生发层增值减缓,棘层增生渐消,基底皮损由厚变薄,说明有效,而基底浸润无改变,肥厚无变薄,则说明无效。
③颜色:由于真皮浅部血管丛和毛细血管的扩张,其皮损多有压不褪色的红色外观。用药后,随着病情的缓解,皮疹的颜色也由红变为淡红,说明有效,否则为无效。
④范围:皮损的多与少,标志着病情的轻与重。用药后,新的皮损停止出现,原有的皮疹从边缘开始缩小,或从中心向边缘逐渐消退,部分大的皮疹分化成若干小块,说明有效,反之则无效。
(2)疗效判断标准:
①显效:在以上四项中,有三项明显好转,或四项均有不同程度的改善;或二项消失,另二项改善。
②有效:有二项改善或一项消失。
③无效:经临床用药一疗程,皮损无改善或加重。
2.治疗结束后临床观察及疗效判断标准
(1)临床观察:
①鳞屑:观察是否有新的鳞屑出现。
②基底:皮疹是否平复,皮肤的光滑度。
③颜色:观察有无色素沉着,或色素脱失。
④范围:观察是否有新的皮疹出现以及原皮损的消退情况。
(2)疗效判断标准:
①临床治愈:皮损全部消退,仅留有色素沉着或脱失。
②显效:皮损消退70%以上。
③有效:皮损消退30-70%之间。
④无效:皮损消退30%以下或未被控制反而加重。
3.远期追访临床观察及疗效判断标准
(1)临床观察:
①时间:治疗结束后一年或二~三年以上,追访痊愈和复发情况。
②病例:追访观察所治愈的病例及复发原因。
(2)疗效判断标准:
①复发:皮损面积比治疗前扩大或加重。
②轻复发:复发皮损为原皮损的50%以下。
五.临床治疗结果
本发明所述的中成药,经对2005-2010年四年内共收治的各类银屑病患者296例进行内服治疗,其中男性146例,女性150例,年龄为16-55岁;其临床治疗结果,按照上述国内统一疗效标准统计计算为:痊愈(停药观察三年以上未复发者)117例,痊愈率为39.53%;显效(停药观察一年以上未复发者)106例,显效率为35.81%;有效(症状明显减轻皮屑大部分脱落,仍有少部分银屑未退者)55例,有效率为18.58%;无效(服药2个疗程不减轻者)18例,无效率6.08%;总有效率为93.92%,未见有任何毒副作用。
典型病例介绍:
1、李长发,男,45岁,家住烟台市芝罘区珠玑村出租车司机,2008年1月16日就诊于本申请人的门诊部,据患者自述患病已6年,多次到医院就诊,均无明显效果至今未治愈。经服用本发明所述的中成药一个疗程后,病症明显有效,此后连续用药6个疗程即痊愈。治疗结束后2年以上追访未复发。
2、冯少军,男,52岁,家住荣城市赤山镇,教师,患银屑病已近20年,经别人介绍于2005年3月12日就诊于本申请人的门诊部,患者自述患病以来多次到医院就诊,也用过别人给的偏方,时好时坏,均无明显效果至今未治愈。经诊断后服用本发明所述的中成药一个疗程后,病症未见明显效果,但感觉有效;患者此后连续用药3个疗程方见到明显疗效;继续服用本发明所述的中成药8个疗程即痊愈。治疗结束后至今已5年以上追访未复发。
3、于爱娟,女,40岁,家住文登市汪疃镇,职工,患银屑病已近10年,经别人介绍于2009年5月18日就诊于本申请人的门诊部,患者自患病以来多次到医院就诊,也用过别人给的偏方,时好时坏,但至今未治愈。经诊断后服用本发明所述的中成药一个疗程后,病症可见明显效果;患者此后连续用药6个疗程即痊愈。治疗结束后至今已1年以上追访未复发。
具体实施方式
实施例1
本实施例所述的中成药是作为治疗银屑病的内服药物,是按下列重量份称取各中药材:丹皮15份、丹参20份、生地15份、茯苓15份、茺蔚子15份、炒荆芥10份、板蓝根15份、金银花15份、紫草15份、白藓皮15份、莪术15份、红花10份、乌梅30份、煅牡蛎60份、赤芍15份、甘草5份。
本实施例的制备工艺为:将上述各药材原料按照常规制备丹剂的制药方法制成丹剂。
实施例2
按下列重量份称取各药材:丹皮45份、丹参50份、生地45份、茯苓45份、茺蔚子45份、炒荆芥40份、板蓝根45份、金银花45份、紫草45份、白藓皮45份、莪术45份、红花30份、乌梅70份、煅牡蛎90份、赤芍45份、甘草35份。
本实施例所述的中成药是作为治疗银屑病的内服药物,其制备工艺为:将上述各药材原料按照常规制备散剂的制药方法制成袋装散剂。
实施例3
按下列重量份称取各药材:丹皮25份、丹参30份、生地25份、茯苓25份、茺蔚子25份、炒荆芥20份、板蓝根25份、金银花25份、紫草25份、白藓皮25份、莪术25份、红花15份、乌梅40份、煅牡蛎70份、赤芍25份、甘草10份。
本实施例所述的中成药是作为治疗银屑病的内服药物,其制备工艺为:将上述各药材原料按照常规制备胶囊剂的制药方法制成胶囊剂。
实施例4
按下列重量份称取各药材:丹皮25-35份、丹参30-40份、生地25-35份、茯苓25-35份、茺蔚子25-35份、炒荆芥20-30份、板蓝根25-35份、金银花25-35份、紫草25-35份、白藓皮25-35份、莪术25-35份、红花15-25份、乌梅40-60份、煅牡蛎70-80份、赤芍25-35份、甘草10-30份。
本实施例所述的中成药是作为治疗银屑病的内服药物,其制备工艺为:将上述各药材原料按照常规制备片剂的制药方法制成片剂,(如普通片剂、糖衣片剂、薄膜衣片剂等),并赋予常规的药物赋形剂(如淀粉、蔗糖、乳糖、硬脂酸钙、硬脂酸镁等)。
实施例5
按下列重量份称取各药材:丹皮30份、丹参35份、生地30份、茯苓30份、茺蔚子30份、炒荆芥25份、板蓝根30份、金银花30份、紫草30份、白藓皮30份、莪术30份、红花20份、乌梅50份、煅牡蛎75份、赤芍30份、甘草20份。
本实施例所述的中成药是作为治疗银屑病的内服药物,其制备工艺为:将上述各药材原料按照常规制备丸剂的制药方法制成丸剂,并赋予常规的药物赋形剂。
实施例6
按下列重量份称取各药材:丹皮30份、丹参35份、生地30份、茯苓30份、茺蔚子30份、炒荆芥25份、板蓝根30份、金银花30份、紫草30份、白藓皮30份、莪术30份、红花20份、乌梅50份、煅牡蛎75份、赤芍30份、甘草20份。
本实施例所述的中成药是作为治疗银屑病的内服药物,其制备工艺为:将上述各药材原料按照常规制备颗粒剂的制药方法制成颗粒剂。
Claims (6)
1.一种治疗银屑病的中成药,其特征是由下列重量份的药物制备而成:丹皮15-45份、丹参20-50份、生地15-45份、茯苓15-45份、茺蔚子15-45份、炒荆芥10-40份、板蓝根15-45份、金银花15-45份、紫草15-45份、白藓皮15-45份、莪术15-45份、红花10-30份、乌梅30-70份、煅牡蛎60-90份、赤芍15-45份、甘草5-35份。
2.根据权利要求1所述的治疗银屑病的中成药,其特征是由下列重量份的药物制备而成:丹皮25-35份、丹参30-40份、生地25-35份、茯苓25-35份、茺蔚子25-35份、炒荆芥20-30份、板蓝根25-35份、金银花25-35份、紫草25-35份、白藓皮25-35份、莪术25-35份、红花15-25份、乌梅40-60份、煅牡蛎70-80份、赤芍25-35份、甘草10-30份。
3.根据权利要求1所述的治疗银屑病的中成药,其特征是由下列重量份的药物制备而成:丹皮30份、丹参35份、生地30份、茯苓30份、茺蔚子30份、炒荆芥25份、板蓝根30份、金银花30份、紫草30份、白藓皮30份、莪术30份、红花20份、乌梅50份、煅牡蛎75份、赤芍30份、甘草20份。
4.根据权利要求1至3任一权利要求所述的治疗银屑病的中成药,其特征是所述的中成药按照中药常规制备技术制成丸剂、丹剂、散剂、片剂、膏剂、汤剂及胶囊装粉剂不同的内服药剂型。
5.根据权利要求4所述的治疗银屑病的中成药,其特征是所述的中成药还含有药物赋形剂。
6.一种权利要求1-3任一权利要求所述的治疗银屑病的中成药,其特征是所述的中成药作为治疗银屑病疾病的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103762963A CN102406893A (zh) | 2011-11-16 | 2011-11-16 | 一种治疗银屑病的中成药 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103762963A CN102406893A (zh) | 2011-11-16 | 2011-11-16 | 一种治疗银屑病的中成药 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102406893A true CN102406893A (zh) | 2012-04-11 |
Family
ID=45909428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103762963A Pending CN102406893A (zh) | 2011-11-16 | 2011-11-16 | 一种治疗银屑病的中成药 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102406893A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103055200A (zh) * | 2013-01-17 | 2013-04-24 | 孟桂梅 | 一种治疗风热型银屑病的中药组合物及其制备方法 |
| CN104689174A (zh) * | 2015-03-13 | 2015-06-10 | 杨洪军 | 银屑病治疗药物和配制方法以及检测方法 |
| CN106344768A (zh) * | 2016-11-11 | 2017-01-25 | 成都悦伦商贸有限公司 | 一种治疗银屑病的中药组合物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2393906A (en) * | 2002-10-10 | 2004-04-14 | Pharma International Pt Herose | Psoriasis treatment |
| CN1562168A (zh) * | 2004-04-08 | 2005-01-12 | 刘晓明 | 用于治疗银屑病的凉血活血复方及其制备方法 |
| CN101632827A (zh) * | 2009-08-21 | 2010-01-27 | 广州中医药大学第二临床医学院 | 一种治疗银屑病的中药组合物及其制备方法 |
| CN101647985A (zh) * | 2009-08-27 | 2010-02-17 | 李志勋 | 一种治疗银屑病的药物组合物 |
-
2011
- 2011-11-16 CN CN2011103762963A patent/CN102406893A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2393906A (en) * | 2002-10-10 | 2004-04-14 | Pharma International Pt Herose | Psoriasis treatment |
| CN1562168A (zh) * | 2004-04-08 | 2005-01-12 | 刘晓明 | 用于治疗银屑病的凉血活血复方及其制备方法 |
| CN101632827A (zh) * | 2009-08-21 | 2010-01-27 | 广州中医药大学第二临床医学院 | 一种治疗银屑病的中药组合物及其制备方法 |
| CN101647985A (zh) * | 2009-08-27 | 2010-02-17 | 李志勋 | 一种治疗银屑病的药物组合物 |
Non-Patent Citations (4)
| Title |
|---|
| 万新区等: ""银屑汤治疗稳定期银屑病40例"", 《湖北中医杂志》 * |
| 康石: "《精选妙用中草药》", 31 December 2008, 吉林科学技术出版社 * |
| 李文亮等: "《千家妙方(下册)》", 31 July 1982, 解放军出版社 * |
| 罗和古等: "《经方验方巧治皮肤病.下册》", 30 September 2007, 中国医药科技出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103055200A (zh) * | 2013-01-17 | 2013-04-24 | 孟桂梅 | 一种治疗风热型银屑病的中药组合物及其制备方法 |
| CN104689174A (zh) * | 2015-03-13 | 2015-06-10 | 杨洪军 | 银屑病治疗药物和配制方法以及检测方法 |
| CN106344768A (zh) * | 2016-11-11 | 2017-01-25 | 成都悦伦商贸有限公司 | 一种治疗银屑病的中药组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102416079A (zh) | 一种治疗白癜风的中成药 | |
| CN102258658A (zh) | 活血止痛膏 | |
| CN102362950A (zh) | 一种治疗白癜风的中药 | |
| CN104399009A (zh) | 治疗肝癌的中药配方及其制备方法 | |
| CN102406867A (zh) | 治疗银屑病的中药 | |
| CN102366541B (zh) | 一种治疗消渴病的中药组合物 | |
| CN1109554C (zh) | 一种治疗过敏性紫癜病的药 | |
| CN104353019A (zh) | 舒经调脏的中药热敷袋及其制备方法 | |
| CN102406866A (zh) | 一种用于治疗银屑病的中药混合物 | |
| CN102423433A (zh) | 一种用于治疗银屑病的中药混合物 | |
| CN101897933B (zh) | 一种治疗白癜风的中成药 | |
| CN102406893A (zh) | 一种治疗银屑病的中成药 | |
| CN102430013A (zh) | 治疗白癜风的中药 | |
| CN102406865A (zh) | 一种治疗银屑病的中药组合物 | |
| CN102579895B (zh) | 一种治疗银屑病的中药组合物 | |
| CN102416117A (zh) | 一种治疗银屑病的中成药 | |
| CN104906430A (zh) | 一种治疗干眼症的中药制剂及其制备方法 | |
| CN104225532A (zh) | 治疗强直性脊柱炎的健脾温肾丸 | |
| CN103860773A (zh) | 用于治疗心肌缺血的中药组合物及其制备方法 | |
| CN102552824B (zh) | 用于治疗银屑病的中成药 | |
| CN103191330A (zh) | 用于治疗偏瘫患者肢体肿胀的中药 | |
| CN102416099A (zh) | 一种治疗银屑病的中药 | |
| CN102423458A (zh) | 一种用于治疗银屑病的中成药 | |
| CN105412626A (zh) | 一种用于治疗颈椎骨质增生的药物制剂及其用途 | |
| CN112263663A (zh) | 一种用于治疗阳虚体质相关妇科疾病的中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120411 |
|
| RJ01 | Rejection of invention patent application after publication |